Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P52630
UPID:
STAT2_HUMAN
Alternative names:
p113
Alternative UPACC:
P52630; B4DLC7; G3V2M6; Q16430; Q16431; Q9UDL4
Background:
Signal transducer and activator of transcription 2 (STAT2), also known as p113, plays a pivotal role in immune response. It mediates signaling by type I interferons, activating antiviral states in cells. STAT2 functions by forming the ISGF3 complex, entering the nucleus to stimulate gene transcription. It also regulates mitochondrial fission, influencing cellular energy dynamics.
Therapeutic significance:
STAT2's involvement in Immunodeficiency 44 and Pseudo-TORCH syndrome 3, diseases characterized by heightened viral susceptibility and severe developmental issues, underscores its therapeutic potential. Targeting STAT2 pathways could lead to innovative treatments for these genetic disorders, offering hope for affected individuals.